Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott North

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
CMAJ Open|July 5, 2022
Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort studyRichard Lee-Ying, Dylan E O'Sullivan, Richard Gagnon, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 7, 2010
Canadian consensus guidelines for the management of testicular germ cell cancerLori Wood, Christian Kollmannsberger, Michael Jewett, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 27, 2022
Canadian Urological Association consensus guideline: Management of testicular germ cell cancerRobert J Hamilton, Christina Canil, Noa Shani Shrem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2017
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerGillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, et al.
The Lancet. Oncology|August 11, 2012
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyLauren C Harshman, Wanling Xie, Georg A Bjarnason, et al.
Clinical Genitourinary Cancer|February 4, 2014
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaNimira Alimohamed, Jae-Lyn Lee, Sandy Srinivas, et al.
Targeted Oncology|January 10, 2013
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patientsMhd Y Al-Marrawi, Brian I Rini, Lauren C Harshman, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 19, 2017
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experienceAly-Khan A Lalani, Haocheng Li, Daniel Y C Heng, et al.
Oncotarget|March 1, 2018
A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209Bernhard Josef Eigl, Kim Chi, Dongsheng Tu, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 14, 2013
Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013Scott North, Naveen Basappa, Georg Bjarnason, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
CMAJ Open|July 5, 2022
Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort studyRichard Lee-Ying, Dylan E O'Sullivan, Richard Gagnon, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 7, 2010
Canadian consensus guidelines for the management of testicular germ cell cancerLori Wood, Christian Kollmannsberger, Michael Jewett, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 27, 2022
Canadian Urological Association consensus guideline: Management of testicular germ cell cancerRobert J Hamilton, Christina Canil, Noa Shani Shrem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2017
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerGillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, et al.
The Lancet. Oncology|August 11, 2012
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyLauren C Harshman, Wanling Xie, Georg A Bjarnason, et al.
Clinical Genitourinary Cancer|February 4, 2014
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaNimira Alimohamed, Jae-Lyn Lee, Sandy Srinivas, et al.
Targeted Oncology|January 10, 2013
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patientsMhd Y Al-Marrawi, Brian I Rini, Lauren C Harshman, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 19, 2017
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experienceAly-Khan A Lalani, Haocheng Li, Daniel Y C Heng, et al.
Oncotarget|March 1, 2018
A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209Bernhard Josef Eigl, Kim Chi, Dongsheng Tu, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 14, 2013
Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013Scott North, Naveen Basappa, Georg Bjarnason, et al.
Pageof 10